Surgical excision of a metastatic adrenal lesion in a patient with prostatic cancer

International Journal of Urology

Volumn 6, Issue 1, 1999, Pages 38-40

  Sakamoto, Naotaka ^a,c   Eto, Masatoshi ^a   Ando, Sadamu ^b  

^a Nakatsu National Hospital   (Japan)

^b KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Adrenal metastasis; Hormone refractory disease; Prostatic cancer; Surgical excision

Indexed keywords

ANDROGEN; ESTRAMUSTINE; GONADORELIN AGONIST; UFT; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADRENAL METASTASIS; ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CASE REPORT; DISEASE COURSE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

ADENOCARCINOMA; ADRENAL GLAND NEOPLASMS; ADRENALECTOMY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 0033513522     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-2042.1999.06125.x     Document Type: Article

References (11)

1. 1 Monte SM, Moore GW, Hutchins GM. Metastatic behavior of prostatic cancer: Cluster analysis of patterns with respect to estrogen treatment. Cancer 1986; 58: 985-93.
2. 2 Saitoh H, Hida M, Shinbo T, Nakamura K, Yamagata J, Satoh T. Metastatic patterns of prostatic cancer: Correlation between sites and number of organs involved. Cancer 1984; 54: 3078-84.
3. 3 Zhang X, Tsukuda F, Yamamoto N, Takenaka I. Brain metastasis from prostate cancer: A case report. Int. J. Urol. 1997; 4: 519-21.
4. 4 Addonizio JC, Thelmo W. Epididymal metastasis from prostatic carcinoma. Urology 1981; 18: 490-1.
5. 5 Seidman AD, Scher HI, Petrylak D, Dershaw D, Curley T. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol. 1992; 147: 931-4.
6. 6 Navarro M, Felip E, Garcia L et al. Addison's disease secondary to prostatic carcinoma: A case report. Tumori 1990; 76: 611-13.
7. 7 Mirtsching BC, Freeman DA. Adrenal insufficiency and stage D carcinoma of the prostate. South. Med. J. 1992; 85: 196-7.
8. 8 Isaacs JT. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 1984; 5: 1-17.
9. 9 Fair WR, Heston WDW. Overview of cancer biology and principles of oncology. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED (eds). Campbell's Urology, 6th edn. WB Saunders Company, Philadelphia, 1992; 1031-52.
10. 10 Stockle M, Meyenburg W, Wellek S et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J. Urol. 1992; 148: 302-7.
11. 11 Hudes GR, Greenberg R, Krigel RL et al. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostatic cancer. J. Clin. Oncol. 1992; 10: 1754-61.